139 results about "IgA antibody" patented technology

The present invention provides binding molecules that include an IgM, IgA, IgG/IgM or IgG/IgA antibody with a modified J-chain that includes a binding moiety that antagonizes a T-cell inhibitory signaling pathway, and their uses.

The invention belongs to the field of biological detection reagents and relates to a kit for indirect ELISA (Enzyme-Linked Immunosorbent Assay) detection of IgG or IgA antibodies of PRRSV (Porcine reproductive and respiratory syndrome virus) of pigs. The kit is used for indirect ELISA detection of the IgG or IgA antibodies of the PRRSV in serum or saliva of pigs and comprises (a) an antibody detection board, (b) an HRP-labeled goat anti-pig IgG antibody solution or HRP-labeled goat anti-pig IgA, (c) a positive control, namely PRRSV standard positive serum or saliva, (d) a negative control, namely PRRSV negative serum or saliva, (e) sample diluting liquid, (f) 10* concentrated washing liquid, (g) substrate developing liquid, and (h) stopping liquid. The kit is good in PRRSV specificity and sensitivity when being used for detection of PRRSV IgG or IgA antibodies in serum or saliva of pigs. A repeatability test also shows that the kit is good in repeatability.

The invention discloses a recombinant helicobacter pylori protein vaccine and a preparation method thereof. The active ingredient recombinant fusion protein of the vaccine consists of recombinant LTAl-Ureal protein and LTB protein, the amino acid sequence of the recombinant LTAl-Ureal protein is shown as Seq ID No.1, the amino acid sequence of the LTB protein is shown as Seq ID No.2. Epitope-containing gene segments of Hp urease A subunit is inserted in an LTA subunit-encoded gene, a toxic part-containing segment is replaced to prepare a recombinant plasmid so as to express and obtain recombinant fusion protein polymer as a vaccine antigen, the fusion antigen and LTB protein pentamer are combined to form a hexamer structure, so that not only can the structure basis and activity of an LT mucosa adjuvant be remained, but also the toxicity can be removed, the immune response of organism muscosa can be effectively induced through immunity of mucosa path, to generate specific IgA antibody. The recombinant helicobacter pylori protein vaccine provides a vaccine manner for preventing and treating infection of helicobacter pylori.

Magnets and magnetic particle-labeled reagents are used to capture and/or release magnetic particle-tagged entities for immunohematology diagnostic testing purposes, especially tests performed in blood banking. The magnetic tagged entities may be tagged antibodies, tagged blood cells, tagged universal binding partners, especially tagged lectins and tagged Coombs reagent, and other binding agents such as biotin-avidin, Protein A or G, ligands and their receptors and the like. Separation of unbound material from bound material is effected through the use of one or both the magnetic field effect on the magnetic labeled reactants and the density gradients of layers of an assay construct. Constructs such as chromatographic strip lateral flow format, and liquid phase reactions in suitable vessels with end point determinations that do not require centrifugation to detect reacted entities. Readable labels such as enzymes, fluorophors, chemiluminescent materials, radioactive isotopes, and other labels may be attached to Coombs reagent to provide a readable product of the Coombs reagent with any antibody participating in the assay.

A novel coronavirus earlier-stage screening method disclosed by the invention can be used for detecting the novel coronavirus, and is particularly used for screening the SARS-CoV-2IgA antibody in theearly stage. A kit comprises an SARS-CoV-2 magnetic bead coating material used as R1, containing a magnetic bead coating material trihydroxymethyl aminomethane buffer solution coated by an SARS-CoV-2recombinant antigen, wherein the pH value is 7.1-7.4; and an acridinium ester marker of the anti-human IgA antibody as R2, wherein the acridinium ester marker is a 2-(N-morpholine) ethanesulfonic acidbuffer solution containing an acridinium ester labeled mouse anti-human IgA monoclonal antibody. The kit and the SARS-CoV-2IgA antibody immunoassay reagent disclosed by the invention can be used forsupplementing and diagnosing new coronal pneumonia at an earlier stage, and have the characteristic of accurate detection result.

The invention provides a novel coronavirus detection test strip as well as a preparation method and application thereof. The test strip comprises a binding pad and an analysis membrane, and the binding pad is coated with a luminescent substance labeled 2019-nCoV recombinant antigen and a mouse anti-human HCG monoclonal antibody; a T2 detection line, a T1 detection line and a quality control line are sequentially arranged on the analysis membrane along the chromatography direction; the T2 detection line is coated with a mouse anti-human IgG monoclonal antibody, the T1 detection line is coated with a mouse anti-human IgA monoclonal antibody and a mouse anti-human IgM monoclonal antibody, and the quality control line is coated with a goat anti-mouse IgG polyclonal antibody. The test paper card can simultaneously determine the positive conditions of IgA antibody, IgM antibody and IgG antibody in serum of a patient, can more accurately detect the early antibody level condition in the body of the patient, assists in judging different periods of novel coronavirus infection of the patient, and improves the sensitivity and specificity of novel coronavirus detection.

The invention relates to a detection kit and detection method for detecting Escherichia coli outer membrane protein C (OmpC) IgA antibody, belonging to the field of immunoassay detection. The OmpC antibody kit provided by the invention comprises a OmpC-coated microporous plate and an enzyme-labeled anti-human IgA antibody. The detection kit provided by the invention has the characteristics of high accuracy, high specificity, high sensitivity and the like, can be used for detecting human body tissue OmpC IgA antibody, and has important functions in diagnosing certain autoimmune diseases.

In the aim of practical utilization of a safe and effective transnasal/inactivated/mucosal vaccine and establishment of a technology for imparting capacity of producing both of IgA and IgG antibodies to a conventional inactivated vaccine, toxoid; allergen, or the like, a means for prevention and treatment of allergy, and the like, it is intended to provide an antigen-drug vehicle (AD vehicle) enabling transnasal, transmucosal, and transdermal administrations, an inactivated vaccine simultaneously inducing a mucosal immunity and humoral immunity by using the AD vehicle, a production method of the inactivated vaccine, an AD vehicle enabling a switch from induction of selective production of IgA antibody to induction of both of IgA and IgG antibodies, and a transnasal vaccine, a mucosal vaccine, a therapeutic/prophylactic agent for allergy, and the like using the AD vehicle.

The invention discloses a detection method for a porcine type A foot-and-mouth disease virus specific IgA antibody; a prokaryotic expression system-expressed foot-and-mouth disease virus VP1 protein is used as a coating antigen, a mouse anti porcine IgA monoclonal antibody is used as a secondary antibody, an enzyme-labeled goat anti mouse IgG antibody is used as an indicator, a to-be-tested sample is subjected to reactions with the coating antigen, the monoclonal antibody and the enzyme-labeled antibody successively, and then is compared with a reference positive sample and a negative sample, and the result can be used for evaluating the level of the porcine foot-and-mouth disease virus specific IgA antibody; and a detection kit is provided. The detection method has the beneficial effects that the invention provides an effective method for evaluating the immune effect of foot-and-mouth disease mucosa and provides a new method for early diagnosis of infection of foot-and-mouth disease, and the foot-and-mouth disease virus specific IgA antibody in porcine nasal swabs can be quickly and accurately detected, sample collection operation is simple, manpower consumption is low, and the stress on animals is small.

The invention provides an influenza virus A IgA antibody immunofluorescence detection test strip, and a preparation method thereof. The influenza virus A IgA antibody immunofluorescence detection teststrip comprises a sample pad, a label pad, a cellulose nitrate membrane, a water absorbent paper, and a backboard; the cellulose nitrate membrane comprises a detection line of influenza virus A NP protein antigen polypeptide fragments, and a human IgA antibody control line; the label pad is provided with anti-human IgA antibody-fluorescence microsphere markers. The influenza virus A IgA antibodyimmunofluorescence detection test strip is extremely high in detection sensitivity; expensive PCR detector is not needed; detection results can be observed with naked eyes; rapid screening on influenza virus A is realized. The invention also provides a detection method and applications of the influenza virus A IgA antibody immunofluorescence detection test strip. The detection method and the stepsare simple; operation is convenient; results are obtained quickly; and the influenza virus A IgA antibody immunofluorescence detection test strip is worthy of wide popularization.

The invention discloses an immunoglobulin M detection reagent, which is provided with simple operation, high accuracy and good reproducibility and strong anti-interference ability; the sample is free from dilution and the detection reagent can be applicable to the immunoglobulin M (IgM) detection reagents of various automatic biochemical analyzers. The immunoglobulin M detection reagent comprises an IgA reagent, an anti-IgA antibody reagent and a liquid serotype constant value calibration liquid; wherein, the IgA reagent enables the IgA antigenic sites in the sample to be fully exposed so as to facilitate the full combination with the anti-IgA antibody reagent; the anti-IgA antibody reagent has high idiosyncrasy with the IgA antigens in human serum; and the liquid serotype constant value calibration liquid is compared with the sample for result calculation.

The invention relates to an EV71 virus IgA antibody detection test strip which comprises a sample pad, a label pad, a nitrocellulose membrane, absorbing paper and a back plate. The nitrocellulose membrane is provided with an EV71 virus VP1 protein antigen peptide fragment detection line and a human IgA antibody control line. The label pad is provided with an an-human IgA anti-body-colloidal gold marker. The EV71 virus IgA antibody detection test strip is used for saliva EV71 virus detection; by detecting an IgA anti-body in a saliva sample, EV71 viruses can be quickly screened, reliability of detection results can be improved, and false-negative conditions are reduced. A detection method is simple to operate, the results are quick, the collection of a detected sample has no invasiveness, and discomfort and cross infection caused by conventional blood sampling and collection of throat swab, anus swab samples and cerebrospinal fluid are avoided.

In one embodiment, the present invention provides for an edible mini-capsule form of live, non-persisting, recombinant Lactococcus lactis (L.lactis) vaccine against a pathogen such as the highly virulent influenza H5N1 strain. Enteric coated capsule of the present invention induced high levels of hemagglutinin-specific serum IgG and fecal IgA antibody production after oral administration in mice and chickens, and rendered complete protection against a lethal challenge of H5N1 virus in mice. The present invention thus demonstrates a broadly applicable platform technology for producing and administering edible vaccines against bacterial and viral infections.

A respiratory syncytial virus IgA antibody detection test strip includes a sample pad, a labeling pad, a nitrocellulose membrane, water absorbent paper and a backing plate and is characterized in that the cellulose membrane comprises a detection line sprayed with a respiratory syncytial virus fusion protein antigen polypeptide fragment and a control line of a human IgA antibody. A saliva specimen is collected by aseptic degreasing cotton, then the saliva specimen is extruded by an injector, the IgA antibody in the saliva is detected by the respiratory syncytial virus IgA antibody rapid chromatography test strip, and the purpose of rapid diagnosis of patient infected respiratory syncytial virus is realized. The method is simple to operate, has rapid results, and is suitable for rapid diagnosis of respiratory syncytial virus infection in medical institutions at all levels. The collected specimen has no invasion, discomfort brought to patients by traditional blood sampling and nasopharyngeal swab collection is avoided, the work efficiency of health care workers is improved, and the promotion rate of respiratory syncytial virus diagnosis in clinic is improved.

The invention provides a novel coronavirus IgA antibody magnetic particle chemiluminiscence method detection kit. The novel coronavirus IgA antibody magnetic particle method detection kit comprises amagnetic particle anti-FITC antibody, an FITC labeled novel coronavirus recombinant antigen and an alkaline phosphatase or horseradish peroxidase labeled human IgA monoclonal antibody. The kit provided by the invention can well supplement diagnosis of a nucleic acid negative new crown infection patient, also shows a good value for diagnosis of an asymptomatic infection patient, can realize early diagnosis and early treatment, reduces a window period as much as possible, and has an important research value for early diagnosis of suspected cases.

The invention discloses an immunoglobulin A detection reagent, comprising an IgA reagent, an anti-IgA antibody reagent and a liquid serotype constant value calibration agent; wherein, the IgA reagent enables the IgA antigenic sites in the sample to be fully exposed so as to facilitate the full combination with the anti-IgA antibody reagent; the anti-IgA antibody reagent has high idiosyncrasy with the IgA antigens in human serum; and the liquid serotype constant value calibration agent is compared with the sample for result calculation. The anti-IgA antibodies are from sheep, horses, rats or rabbits and other mammals. The IgA reagent and the anti-IgA antibody reagent can be used as two separate reagents to compose the double-reagent form of the product, and can also be mixed based on a certain percentage to constitute the single-reagent form of the product.